# Axel Grothey

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/axel-grothey/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,998 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 77 |
| i10-index | 238 |
| Last Known Institution | Campbell Clinic |
| OpenAlex ID | https://openalex.org/A5057458005 |
| ORCID iD | https://orcid.org/0000-0002-9341-6499 |
| Works | 583 |

## Researcher papers

- [Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy](https://scholariq.org/papers/improved-survival-in-metastatic-colorectal-cancer-is-associated-with-adoption-of/)
- [Duration of Adjuvant Chemotherapy for Stage III Colon Cancer](https://scholariq.org/papers/duration-of-adjuvant-chemotherapy-for-stage-iii-colon-cancer/)
- [Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study](https://scholariq.org/papers/ramucirumab-versus-placebo-in-combination-with-second-line-folfiri-in-patients/)
- [Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials](https://scholariq.org/papers/treatment-related-adverse-events-of-pd-1-and-pd-l1-inhibitors-in-clinical-trials/)
- [Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies](https://scholariq.org/papers/chemotherapy-induced-peripheral-neuropathy-prevention-and-treatment-strategies/)
- [Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-esmo-consensus-guidelines-for-the-management-of-patients-with/)
- [Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841](https://scholariq.org/papers/treatment-of-colorectal-peritoneal-carcinomatosis-with-systemic-chemotherapy-a/)
- [Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer](https://scholariq.org/papers/factors-predicting-response-perioperative-outcomes-and-survival-following-total/)
- [Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7](https://scholariq.org/papers/intravenous-calcium-and-magnesium-for-oxaliplatin-induced-sensory-neurotoxicity/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Campbell Clinic](https://scholariq.org/institutions/campbell-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.